Efforts to improve the Company’s financial results
The Company has incurred losses over the past years. Management is making every effort and continues to implement changes designed to significantly improve the Company’s financial results and operating cash flows. The actions involve certain cost-saving initiatives and growth strategies, including:
(a) Improve capital conditions Taking steps to improve the capital conditions, including increasing our bank loan and attracting new investment.(b) Expand the market for our products by increasing marketing activities and sales Manufacturing some drugs that we did not make before, increasing marketing activities and instituting polices to motivate salespersons to increase sales.
(c) Strengthen internal controls Taking steps to strengthen internal controls aimed at bringing down production costs and various expenses.
(d) Continue our cooperation with Yangling Daiying Biotech Institute Continue cooperation with Yangling Daiying Biotech Institute on the manufacturing and sale of its SFDA-approved product Emergency Haemostatic Patch, as well as increasing other incomes.
Management believes that these actions will enable the Company to improve future profitability and cash flow in its continuing operations through December 31, 2010.
Pharma
worldwidebio.com